Insider Trading Activity bluebird bio, Inc. (NASDAQ:BLUE) – Director Sold 1,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For bluebird bio, Inc. (NASDAQ:BLUE)

James Mandell , Director of bluebird bio, Inc. (NASDAQ:BLUE) reportedly Sold 1,000 shares of the company’s stock at an average price of 95.95 for a total transaction amount of $95,950.00 SEC Form

Insider Trading History For bluebird bio, Inc. (NASDAQ:BLUE)

  • On 1/3/2014 Linda Bain, VP, sold 5,000 with an average share price of $20.89 per share and the total transaction amounting to $104,450.00.View SEC Filing
  • On 1/3/2014 David Davidson, Insider, sold 15,000 with an average share price of $20.88 per share and the total transaction amounting to $313,200.00.View SEC Filing
  • On 1/10/2014 Jeffrey Walsh, COO, sold 6,000 with an average share price of $21.98 per share and the total transaction amounting to $131,880.00.View SEC Filing
  • On 1/14/2014 Robert Tepper, Director, sold 340,000 with an average share price of $21.90 per share and the total transaction amounting to $7,446,000.00.View SEC Filing
  • On 1/16/2014 Mitchell Finer, Insider, sold 10,000 with an average share price of $23.52 per share and the total transaction amounting to $235,200.00.View SEC Filing
  • On 1/17/2014 Robert Tepper, Director, sold 307,000 with an average share price of $22.43 per share and the total transaction amounting to $6,886,010.00.View SEC Filing
  • On 1/22/2014 Linda Bain, VP, sold 2,500 with an average share price of $25.11 per share and the total transaction amounting to $62,775.00.View SEC Filing

    • Analyst Ratings For bluebird bio, Inc. (NASDAQ:BLUE)
    These are 2 Sell Ratings, 5 Hold Ratings, 11 Buy Ratings .
    The current consensus rating for bluebird bio, Inc. (NASDAQ:BLUE) is Buy (Score: 2.50) with a consensus target price of $99.58 , a potential (2.60% upside)

    Analyst Ratings History For bluebird bio, Inc. (NASDAQ:BLUE)

    • On 11/5/2015 Oppenheimer Holdings, Inc. Reiterated Rating Outperform with a price target of $162.00
    • On 5/5/2016 Wells Fargo & Company Reiterated Rating Buy
    • On 10/14/2016 SunTrust Banks, Inc. Reiterated Rating Buy
    • On 10/15/2016 Goldman Sachs Group, Inc. (The) Reiterated Rating Buy with a price target of $135.00
    • On 11/30/2016 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $95.00
    • On 12/1/2016 Leerink Swann Boost Price Target of rating Outperform with a price target of $80.00 to $85.00
    • On 12/7/2016 J P Morgan Chase & Co Reiterated Rating Buy with a price target of $120.00

    Recent Trading Activity for bluebird bio, Inc. (NASDAQ:BLUE)
    Shares of bluebird bio, Inc. closed the previous trading session at 97.05 up +0.45 0.47% with 313,313 shares trading hands.